(secondQuint)Arsenic Trioxide in Treating Patients With Multiple Myeloma.

 OBJECTIVES: I.

 Determine the response rate of patients with relapsed or refractory stage II or III multiple myeloma treated with arsenic trioxide.

 II.

 Determine the overall and relapse-free survival rates of patients treated with this drug.

 III.

 Determine the safety profile of this drug in these patients.

 OUTLINE: Patients receive arsenic trioxide IV on days 1-5 and 8-12.

 Treatment repeats every 4 weeks for up to 6 courses.

 Patients are followed at 4 weeks after the last treatment dose.

 PROJECTED ACCRUAL: A total of 55 patients will be accrued for this study.

.

 Arsenic Trioxide in Treating Patients With Multiple Myeloma@highlight

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.

 PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have relapsed or refractory stage II or stage III multiple myeloma.

